( New Data Presented at EULAR Confirms E...)Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis,Health

New Data Presented at EULAR Confirms Efficacy with Either Every Two Weeksn or Monthly Dosing

BARCELONA, Spain, 14 June 2007 - 7:00 am CET - New pivotal data (RAPID 1 and RAPID 2) presented at the Annual European Congress of Rheumatology (EULAR) show that Cimzia (certolizumab pegol), the first PEGylated, Fc-free anti-TNF, combined with methotrexate therapy has a rapid and significant effect in reducing the signs and symptoms of active rheumatoid arthritis (RA) compared with methotrexate alone. Data from a third study, the 011 trial, presented at the conference also showed that Cimzia given every four weeks as monotherapy is significantly more efficacious than placebo in the treatment of patients with active RA who had previously failed
disease-modifying anti-rheumatic drug (DMARD) therapy.

In both pivotal Phase III studies, RAPID 1 and RAPID 2, the primary endpoint, ACR20[a] response at 24 weeks, was significantly higher in
both CIMZIA(TM) treated arms (400 mg at week zero, week two and week four followed by 200 mg every two weeks plus methotrexate; or 400 mg every two weeks plus methotrexate) compared with the placebo plus methotrexate-treated arm (p<0.001). In both studies there was no significant difference between response levels in either of the CIMZIA(TM) treatment arms. ACR50 and ACR70 responses were also achieved rapidly and with statistical significance in both studies in the CIMZIA(TM) treated arms.

RAPID 1 and RAPID 2 demonstrated that effective results in the treatment of RA can be achieved with a 200 mg every other week dose
of CIMZIA(TM) -- the higher dose is not necessary. CIMZIA(TM) was also shown to have a rapid onset of action: in RAPID 1, a 25.4% ACR50 response rate was observed at week 8 in both treatment groups.

"These results are significant. They showed, for the first time, that the Fc region present in conventional anti-TNFs is not required
'"/>